333 related articles for article (PubMed ID: 29260356)
1. Brain diffusion tensor imaging changes in cerebrotendinous xanthomatosis reversed with treatment.
Catarino CB; Vollmar C; Küpper C; Seelos K; Gallenmüller C; Bartkiewicz J; Biskup S; Hörtnagel K; Klopstock T
J Neurol; 2018 Feb; 265(2):388-393. PubMed ID: 29260356
[TBL] [Abstract][Full Text] [Related]
2. Differing clinical features between Japanese siblings with cerebrotendinous xanthomatosis with a novel compound heterozygous CYP27A1 mutation: a case report.
Koyama S; Okabe Y; Suzuki Y; Igari R; Sato H; Iseki C; Tanji K; Suzuki K; Ohta Y
BMC Neurol; 2022 May; 22(1):193. PubMed ID: 35614401
[TBL] [Abstract][Full Text] [Related]
3. The wide spectrum of cerebrotendinous xanthomatosis: Case report of a rare but treatable disease.
Rosafio F; Cavallieri F; Guaraldi P; Taroni F; Nichelli PF; Mandrioli J
Clin Neurol Neurosurg; 2016 Apr; 143():1-3. PubMed ID: 26874936
[TBL] [Abstract][Full Text] [Related]
4. Patients with Lately Diagnosed Cerebrotendinous Xanthomatosis.
Yunisova G; Tufekcioglu Z; Dogu O; Bilgic B; Kaleagasi H; Akca Kalem S; Lohmann E; Gurvit HI; Emre M; Hanagasi HA
Neurodegener Dis; 2019; 19(5-6):218-224. PubMed ID: 32349000
[TBL] [Abstract][Full Text] [Related]
5. Cerebrotendinous Xanthomatosis ataxia responsive to CDCA and Riluzole.
Weissfeld T; Ratliff J
J Clin Neurosci; 2018 Jul; 53():263-264. PubMed ID: 29731275
[TBL] [Abstract][Full Text] [Related]
6. Three siblings with Cerebrotendinous Xanthomatosis: a novel mutation in the CYP27A1 gene.
Suh S; Kim HK; Park HD; Ki CS; Kim MY; Jin SM; Kim SW; Hur KY; Kim KW; Kim JH
Eur J Med Genet; 2012 Jan; 55(1):71-4. PubMed ID: 21958693
[TBL] [Abstract][Full Text] [Related]
7. Cerebrotendinous xanthomatosis (CTX): a treatable lipid storage disease.
Keren Z; Falik-Zaccai TC
Pediatr Endocrinol Rev; 2009 Sep; 7(1):6-11. PubMed ID: 19696711
[TBL] [Abstract][Full Text] [Related]
8. A novel frameshift mutation in the sterol 27-hydroxylase gene in an Egyptian family with cerebrotendinous xanthomatosis without cataract.
Abdel-Hamid MS; Issa MY; Otaify GA; Zaki MS
Metab Brain Dis; 2017 Apr; 32(2):311-315. PubMed ID: 28229379
[TBL] [Abstract][Full Text] [Related]
9. Using fiber tractography and diffusion kurtosis imaging to evaluate neuroimaging changes in patients with cerebrotendinous xanthomatosis after stopping chenodeoxycholic acid treatment for three years.
Lee JJ; Chang CC; Chang WN
Biomed J; 2022 Oct; 45(5):814-820. PubMed ID: 34543727
[TBL] [Abstract][Full Text] [Related]
10. Treatment with chenodeoxycholic acid in cerebrotendinous xanthomatosis: clinical, neurophysiological, and quantitative brain structural outcomes.
Amador MDM; Masingue M; Debs R; Lamari F; Perlbarg V; Roze E; Degos B; Mochel F
J Inherit Metab Dis; 2018 Sep; 41(5):799-807. PubMed ID: 29560583
[TBL] [Abstract][Full Text] [Related]
11. [Cerebrotendinous xanthomatosis. Report of one case].
Contreras JP; Guajardo G; Martínez A; López I; Cea G
Rev Med Chil; 2019 May; 147(5):658-662. PubMed ID: 31859899
[TBL] [Abstract][Full Text] [Related]
12. A case of Cerebrotendinous Xanthomatosis with spinal cord involvement and without tendon xanthomas: identification of a new mutation of the CYP27A1 gene.
Gelzo M; Di Taranto MD; Bisecco A; D'Amico A; Capuano R; Giacobbe C; Caputo M; Cirillo M; Tedeschi G; Fortunato G; Corso G
Acta Neurol Belg; 2021 Apr; 121(2):561-566. PubMed ID: 31875301
[TBL] [Abstract][Full Text] [Related]
13. [Cerebrotendinous xanthomatosis, a treatable metabolic disorder].
Heller R; Grau AJ; Schäbitz WR; Schwaninger M
Nervenarzt; 2002 Dec; 73(12):1160-6. PubMed ID: 12486565
[TBL] [Abstract][Full Text] [Related]
14. Clinical report: A patient with a late diagnosis of cerebrotendinous xanthomatosis and a response to treatment.
Alhariri A; Hamilton K; Oza V; Cordoro K; Sobreira NL; Malloy M; Slavotinek A
Am J Med Genet A; 2017 Aug; 173(8):2275-2279. PubMed ID: 28590052
[TBL] [Abstract][Full Text] [Related]
15. [Cerebrotendinous xanthomatosis: a multicentric retrospective study of 15 adults, clinical and paraclinical typical and atypical aspects].
Lionnet C; Carra C; Ayrignac X; Levade T; Gayraud D; Castelnovo G; Besson G; Androdias G; Vukusic S; Confavreux C; Zaenker C; De Seze J; Collongues N; Blanc F; Tranchant C; Wallon D; Hannequin D; Gerdelat-Mas A; Brassat D; Clanet M; Zephir H; Outteryck O; Vermersch P; Labauge P
Rev Neurol (Paris); 2014; 170(6-7):445-53. PubMed ID: 24746394
[TBL] [Abstract][Full Text] [Related]
16. A case of cerebrotendinous xanthomatosis presenting with epilepsy as an initial symptom with a novel V413D mutation in the CYP27A1 gene.
Koyama S; Kawanami T; Tanji H; Arawaka S; Wada M; Saito N; Kato T
Clin Neurol Neurosurg; 2012 Sep; 114(7):1021-3. PubMed ID: 22336472
[No Abstract] [Full Text] [Related]
17. Chenodeoxycholic acid (CDCA) treatment during pregnancy in women with cerebrotendinous xanthomatosis (CTX): Lessons learned from 19 pregnancies.
Zaccai TCF; Hassin-Baer S; Kfir NC; Duell PB; Neerhof M; Sloma R; Roitman M; Kisanuki YY; Verrips A; DeBarber AE
Genet Med; 2024 May; 26(5):101086. PubMed ID: 38288684
[TBL] [Abstract][Full Text] [Related]
18. [Cerebrotendinous xanthomatosis is a rare disorder, which requires a specific treatment].
Blaabjerg M; Marjanovic D
Ugeskr Laeger; 2013 Jan; 175(5):285-6. PubMed ID: 23369332
[TBL] [Abstract][Full Text] [Related]
19. Late-onset Cerebrotendinous Xanthomatosis with a Novel Mutation in the CYP27A1 Gene.
Sasamura A; Akazawa S; Haraguchi A; Horie I; Ando T; Abiru N; Takei H; Nittono H; Une M; Kurosawa T; Murai T; Naruse H; Nakayama T; Kotani K; Remaley AT; Kawakami A
Intern Med; 2018 Jun; 57(11):1611-1616. PubMed ID: 29434128
[TBL] [Abstract][Full Text] [Related]
20. The safety and effectiveness of chenodeoxycholic acid treatment in patients with cerebrotendinous xanthomatosis: two retrospective cohort studies.
Verrips A; Dotti MT; Mignarri A; Stelten BML; Verma S; Federico A
Neurol Sci; 2020 Apr; 41(4):943-949. PubMed ID: 31863326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
